Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    Positive Results for Combination Ricin, Anthrax Vaccine

    By Global Biodefense StaffJuly 14, 2014
    Biodefense Vaccine Development
    Credit: Shutterstock
    Share
    Facebook LinkedIn Reddit Email

    Soligenix, Inc. last week announced positive results for the combination of RiVax and VeloThrax to induce protective immunity to both ricin toxin and anthrax toxin exposure.

    RiVax is the company’s candidate vaccine for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. VeloThrax employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine.

    When administered as single a vaccine, each vaccine induced antibodies that were capable of neutralizing the toxin from which the vaccine had been derived.  VeloThrax induced neutralizing antibodies against anthrax toxin and RiVax induced antibodies against ricin toxin.  When combined, the dual vaccine induced antibodies that were reactive against both toxins and these neutralizing antibodies were detected until at least 200 days after the immunization regimens.

    Consequently, the combined vaccination provided protection to exposure to both ricin toxin and anthrax toxin that persisted for at least six months after 2 vaccinations, suggesting that long-term immunity upon simultaneous vaccination can be achieved.

    Soligenix performed these studies in collaboration with the Wadsworth Institute of the New York State Department of Health, with Dr. Nicolas J. Mantis, Dr. David Vance and collaborators under the aegis of a $9.4 million cooperative grant from the National Institute of Allergy and Infectious Diseases (NIAID). The potency of the vaccine combination was demonstrated in preclinical studies evaluating both production of antibody levels and survival after toxin challenge.

    “We are pleased that we have been able to show that the combination of vaccines for these two very important biothreats can be accomplished.  The demonstration of simultaneous immunity to ricin toxin and anthrax is a step towards multivalent vaccines that can be used in the event of a national emergency,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix.

    “Both of these vaccines are being developed for military personnel and emergency first responders, and thus it would be extremely useful if the vaccines could be administered simultaneously without compromising the response to either vaccine, while still providing protection against whichever toxin might be encountered,” said Schaber. “Multivalent vaccines will achieve more efficient vaccination with fewer injections; this has the potential to be a distinct advantage in deployment of vaccines if any biothreat agent is actually used as a weapon and will be more useful for vaccination of military personnel and first responders. We intend to develop the combination vaccine using ThermoVax, our proprietary system for stabilizing vaccines for stockpiling and for distribution of vaccines outside of normal cold chain requirements.”

    Source: Soligenix, Inc. press release, adapted. RiVax and VeloThrax and ThermoVax are trademarked terms of Soligenix.

    Anthrax Bioterrorism NIAID Ricin Strategic National Stockpile Thermostability Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleTranscript of CDC Press Conference on Biosafety Incidents
    Next Article CBRNE Team Validates Heavy Expeditionary Laboratory

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Mass Spec for Rapid Detection of Biological Warfare Agents

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy